Publikationen in Zusammenarbeit mit Forschern von Eli Lilly and Company (15)

2024

  1. Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects

    Diabetes Therapy

2022

  1. Mapping genomic loci implicates genes and synaptic biology in schizophrenia

    Nature, Vol. 604, Núm. 7906, pp. 502-508

2021

  1. Epidemiology and Economic Burden of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in Spain: A Systematic Review

    Diabetes Therapy, Vol. 12, Núm. 6, pp. 1631-1659

2016

  1. A comprehensive fracture prevention strategy in older adults: The European union geriatric medicine society (EUGMS) statement

    European Geriatric Medicine, Vol. 7, Núm. 6, pp. 519-525

2012

  1. Delphi consensus on the physical health of patients with schizophrenia: Evaluation of the recommendations of the Spanish societies of psychiatry and biological psychiatry by a panel of experts

    Actas Espanolas de Psiquiatria, Vol. 40, Núm. 3, pp. 114-128

2011

  1. Clinical meaningful outcomes in schizophrenia: Remission and recovery

    Revista de Psiquiatria y Salud Mental, Vol. 4, Núm. 1, pp. 53-65

2009

  1. Pemetrexed in first-line treatment of non-small cell lung cancer

    Cancer Treatment Reviews, Vol. 35, Núm. 4, pp. 364-373

2007

  1. Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer

    Annals of Oncology, Vol. 18, Núm. 8, pp. 1359-1362

  2. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: Prevalence and associations in a cross-sectional study

    European Psychiatry, Vol. 22, Núm. 8, pp. 490-498

2005

  1. Safety and effectiveness of olanzapine in monotherapy: A multivariate analysis of a naturalistic study

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 29, Núm. 6, pp. 944-951

  2. Safety, effectiveness, and patterns of use of olanzapine in acute schizophrenia: A multivariate analysis of a large naturalistic study in the hospital setting

    Medicina Clinica, Vol. 124, Núm. 13, pp. 481-486

2004

  1. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

    Journal of the National Cancer Institute, Vol. 96, Núm. 23, pp. 1751-1761

2003

  1. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 27, Núm. 3, pp. 473-481

  2. Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

    European Neuropsychopharmacology, Vol. 13, Núm. 1, pp. 39-48

2002

  1. Características de la versión española del cuestionario de calidad de vida QLSM-H en sujetos adultos con deficiencia de hormona de crecimiento tratados con somatotropina. Estudio piloto

    Endocrinologia y Nutricion, Vol. 49, Núm. 4, pp. 105-112